Table 1 Baseline cohort characteristics in the original UK model development cohort and Prostate Cancer data Base Sweden (PCBaSe) cohort
UK model development cohort | Sweden PCBase cohort | |||
|---|---|---|---|---|
Total subjects | 7063 | 69,206 | ||
Time at risk (years) | 58,138 | 589,733 | ||
Range | Range | |||
Median follow-up (years) | 9.8 | 0–16 | 13.9 | 0–17 |
Age (mean, SD) | 69.9 | 8.34 | 68.8 | 8.83 |
PSA (mean, SD) | 18.5 | 17.5 | 15.7 | 17.0 |
Grade groups | % | % | ||
1 | 2317 | 32.8 | 36,992 | 53.5 |
2 | 2125 | 30.1 | 14,015 | 20.3 |
3 | 1057 | 15.0 | 7774 | 11.2 |
4 | 710 | 10.1 | 6345 | 9.2 |
5 | 854 | 12.1 | 4080 | 5.9 |
T stage | ||||
1 | 3761 | 53.2 | 35,700 | 51.6 |
2 | 2270 | 32.1 | 22,478 | 32.5 |
3 | 977 | 13.8 | 10,295 | 14.9 |
4 | 55 | 0.8 | 733 | 1.1 |
Primary treatment | ||||
Radical prostatectomy | 995 | 14.1 | 20,936 | 30.3 |
Radical radiotherapy | 2457 | 34.8 | 11,906 | 17.2 |
Androgen deprivation monotherapy | 2226 | 31.5 | 15,980 | 23.1 |
Conservative management | 1385 | 19.6 | 20,384 | 29.5 |
Comorbidity | ||||
No recorded comorbidity | 6363 | 90.1 | 62,173 | 89.8 |
Comorbidity (Charlson Score ≥ 1) | 700 | 9.9 | 7033 | 10.2 |
10-year outcomes | ||||
PCa death | 712 | 6993 | ||
Non-PCa death | 1555 | 15,122 | ||
Any-cause death | 2267 | 22,115 | ||
Overall outcomes | ||||
PCa death | 846 | 8151 | ||
Non-PCa death | 1829 | 18,003 | ||
Any-cause death | 2675 | 26,154 | ||
Crude PCS mortality rate (per patient year) | 1.46 | 1.38 | ||
Annual overall mortality rate (per patient year) | 4.60 | 4.43 | ||